Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Phase 3 Completed

143 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT04534075 2025-09-08

FIDURA

Phase 3 Completed

354 enrolled

GastrointestinalGenitourinaryGynecologic

Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Flatulence, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

NCT00092534 2025-08-01

FUTURE II

Phase 3 Completed

12,167 enrolled 23 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT01101451 2025-05-23

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Phase 3 Completed

340 enrolled 13 charts

Gynecologic

Uterine Cervical Neoplasms

NCT03308591 2024-10-31

Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients

Phase 3 Completed

774 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05564286 2024-02-06

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Phase 3 Completed

116 enrolled

GynecologicHead & Neck

Uterine Cervical Neoplasms, Nasopharyngeal Neoplasms, Vomiting

NCT05372016 2023-11-24

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,200 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT04782895 2023-06-15

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Phase 3 Completed

488 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT02997553 2023-01-09

GASVERT

Phase 3 Completed

744 enrolled

BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT01414608 2022-11-07

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Phase 3 Completed

926 enrolled 13 charts

Gynecologic

Uterine Cervical Neoplasms

NCT01470677 2022-07-08

Tachosil for the Prevention of Symptomatic Lymph Cysts

Phase 3 Completed

220 enrolled

Gynecologic

Uterine Cervical Neoplasms, Lymphocele, Neoplasms, Endometrial Neoplasms

NCT03476018 2022-06-16

Trial to Optimally Show the Pharmacological Action of Z-100

Phase 3 Completed

72 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02247232 2022-03-04

Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer

Phase 3 Completed

793 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04425291 2022-02-25

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Phase 3 Completed

1,680 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT00001073 2021-11-04

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

Phase 3 Completed

150 enrolled

Gynecologic

Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Uterine Cervical Diseases, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, HIV Infections

NCT03413579 2021-08-25

CIMAHOPE

Phase 3 Completed

37 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasms

NCT01536392 2021-06-11

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Phase 3 Completed

76 enrolled 8 charts

Gynecologic

Uterine Cervical Neoplasms, Nausea, Vomiting

NCT01365156 2021-02-03

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

Phase 3 Completed

28 enrolled 8 charts

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Phase 3 Completed

525 enrolled 24 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT04237090 2020-10-12

PREMED-F1

Phase 3 Completed

27 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00006083 2020-08-03

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

Phase 3 Completed

DermatologicGynecologicLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Burkitt Lymphoma, Uterine Cervical Neoplasms, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Precancerous Conditions, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Phase 3 Completed

1,447 enrolled 26 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00016380 2020-04-03

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

Phase 3 Completed

211 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Appendiceal Neoplasms, Bile Duct Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Nausea, Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Vomiting, Seminoma

NCT03546842 2020-02-25

V503-017

Phase 3 Completed

201 enrolled 11 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT01735006 2020-02-24

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Phase 3 Completed

7,372 enrolled

Gynecologic

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Phase 3 Completed

152 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Phase 3 Completed

5,752 enrolled 42 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Phase 3 Completed

1,106 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Phase 3 Completed

1,212 enrolled 15 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Phase 3 Completed

34 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00937950 2019-10-29

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Phase 3 Completed

2,022 enrolled 10 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00128661 2019-03-08

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Phase 3 Completed

7,466 enrolled 24 charts

GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

NCT01376349 2019-02-07

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Phase 3 Completed

464 enrolled 8 charts

BreastGynecologicOther

Carcinoma, Ovarian Epithelial, Anxiety Disorders, Breast Neoplasms, Uterine Cervical Neoplasms, Depression, Fallopian Tube Neoplasms, Sexual Dysfunction, Physiological, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT01254643 2018-11-28

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Phase 3 Completed

100 enrolled 8 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01047345 2018-11-27

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Phase 3 Completed

924 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Phase 3 Completed

250 enrolled 20 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00064077 2018-10-17

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Phase 3 Completed

513 enrolled 15 charts

Gynecologic

Uterine Cervical Neoplasms

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Phase 3 Completed

100 enrolled 9 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

744 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00345878 2018-07-20

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Phase 3 Completed

271 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT02765919 2018-07-16

A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix

Phase 3 Completed

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00799825 2018-07-12

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Phase 3 Completed

346 enrolled 8 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Clinical Trials

innovaTV 301

KEYNOTE-A18

PARCER

KEYNOTE-826

NOVEL

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

FIDURA

FUTURE II

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

GASVERT

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Tachosil for the Prevention of Symptomatic Lymph Cysts

Trial to Optimally Show the Pharmacological Action of Z-100

Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors

CIMAHOPE

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

PREMED-F1

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

V503-017

Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US